baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Check Point Software Technologies.../ IL0010824113 /

2024-04-24 9:59:07 PM	Chg. -	Volume	Bid10:25:00 PM	Ask1:43:58 AM	Market Capitalization	Dividend Y.	P/E Ratio
160.96USD	-	63,960 Turnover: 5.24 mill.	-Bid Size: -	-Ask Size: -	18.82 bill.USD	-	22.39

GlobeNewswire 2:00 PM Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

GlobeNewswire 2:00 PM Aqua Security Appoints Mike Dube as Chief Revenue Officer

GlobeNewswire 1:00 PM Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...

GlobeNewswire 3:00 AM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Che...

GlobeNewswire 04-24 NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

GlobeNewswire 04-24 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Socie...

GlobeNewswire 04-24 Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Stu...

GlobeNewswire 04-24 DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...

GlobeNewswire 04-24 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...

GlobeNewswire 04-24 SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc....

GlobeNewswire 04-24 BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investiga...

GlobeNewswire 04-24 Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antib...

GlobeNewswire 04-24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 04-24 Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 Amer...

GlobeNewswire 04-24 ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual...

GlobeNewswire 04-24 Immunocore announces upcoming presentation and posters at ASCO 2024

GlobeNewswire 04-24 Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American S...

GlobeNewswire 04-23 OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ON...

GlobeNewswire 04-23 PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATIL...

GlobeNewswire 04-23 INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ch...

TeleTrader 04-23 Israeli forces shoot 5 in West Bank incidents

GlobeNewswire 04-22 Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Agains...

GlobeNewswire 04-22 CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...

GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 04-21 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel...

Check Point Software Technologies.../ IL0010824113 /

If you wish to receive reply to your feedback, please provide your email address.